TTR and amyloidosis: Safety and efficacy evaluation of fx-1006a in patients with v122i or wild-type transthyretin (ttr) amyloid cardiomyopathy Endpoint: safety/efficacyPhase 3:non-randomized, open-label evaluation of Tafamidis in patients with TTR amyloidosis